These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25605352)

  • 1. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.
    Stickles AM; de Almeida MJ; Morrisey JM; Sheridan KA; Forquer IP; Nilsen A; Winter RW; Burrows JN; Fidock DA; Vaidya AB; Riscoe MK
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1977-82. PubMed ID: 25605352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
    McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
    ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.
    Stickles AM; Smilkstein MJ; Morrisey JM; Li Y; Forquer IP; Kelly JX; Pou S; Winter RW; Nilsen A; Vaidya AB; Riscoe MK
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4853-9. PubMed ID: 27270285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antimalarial compound ELQ-400 is an unusual inhibitor of the bc
    Song Z; Iorga BI; Mounkoro P; Fisher N; Meunier B
    FEBS Lett; 2018 Apr; 592(8):1346-1356. PubMed ID: 29574797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Ubiquinol-Reduction (Q
    Amporndanai K; Pinthong N; O'Neill PM; Hong WD; Amewu RK; Pidathala C; Berry NG; Leung SC; Ward SA; Biagini GA; Hasnain SS; Antonyuk SV
    Biology (Basel); 2022 Jul; 11(8):. PubMed ID: 35892964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-
    Nguyen W; Dans MG; Currie I; Awalt JK; Bailey BL; Lumb C; Ngo A; Favuzza P; Palandri J; Ramesh S; Penington J; Jarman KE; Mukherjee P; Chakraborty A; Maier AG; van Dooren GG; Papenfuss T; Wittlin S; Churchyard A; Baum J; Winzeler EA; Baud D; Brand S; Jackson PF; Cowman AF; Sleebs BE
    ACS Infect Dis; 2023 Mar; 9(3):668-691. PubMed ID: 36853190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.
    Stickles AM; Ting LM; Morrisey JM; Li Y; Mather MW; Meermeier E; Pershing AM; Forquer IP; Miley GP; Pou S; Winter RW; Hinrichs DJ; Kelly JX; Kim K; Vaidya AB; Riscoe MK; Nilsen A
    Am J Trop Med Hyg; 2015 Jun; 92(6):1195-201. PubMed ID: 25918204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex.
    Siregar JE; Kurisu G; Kobayashi T; Matsuzaki M; Sakamoto K; Mi-ichi F; Watanabe Y; Hirai M; Matsuoka H; Syafruddin D; Marzuki S; Kita K
    Parasitol Int; 2015 Jun; 64(3):295-300. PubMed ID: 25264100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimalarial quinolones: synthesis, potency, and mechanistic studies.
    Winter RW; Kelly JX; Smilkstein MJ; Dodean R; Hinrichs D; Riscoe MK
    Exp Parasitol; 2008 Apr; 118(4):487-97. PubMed ID: 18082162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
    Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
    PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDQ, a potent inhibitor of Plasmodium falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 complex.
    Vallières C; Fisher N; Antoine T; Al-Helal M; Stocks P; Berry NG; Lawrenson AS; Ward SA; O'Neill PM; Biagini GA; Meunier B
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3739-47. PubMed ID: 22547613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytochrome b lysine 329 residue is critical for ubihydroquinone oxidation and proton release at the Q
    Francia F; Khalfaoui-Hassani B; Lanciano P; Musiani F; Noodleman L; Venturoli G; Daldal F
    Biochim Biophys Acta Bioenerg; 2019 Feb; 1860(2):167-179. PubMed ID: 30550726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconstructing the Qo site of Plasmodium falciparum bc 1 complex in the yeast enzyme.
    Vallières C; Fisher N; Meunier B
    PLoS One; 2013; 8(8):e71726. PubMed ID: 23951230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome bc1 complex [2Fe-2S] cluster and its interaction with ubiquinone and ubihydroquinone at the Qo site: a double-occupancy Qo site model.
    Ding H; Robertson DE; Daldal F; Dutton PL
    Biochemistry; 1992 Mar; 31(12):3144-58. PubMed ID: 1313287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii.
    Alday PH; Bruzual I; Nilsen A; Pou S; Winter R; Ben Mamoun C; Riscoe MK; Doggett JS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods.
    Akhoon BA; Singh KP; Varshney M; Gupta SK; Shukla Y; Gupta SK
    PLoS One; 2014; 9(10):e110041. PubMed ID: 25334024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Endochin-Like Quinolones Exhibit Potent
    van Schalkwyk DA; Riscoe MK; Pou S; Winter RW; Nilsen A; Duffey M; Moon RW; Sutherland CJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of
    Lane KD; Mu J; Lu J; Windle ST; Liu A; Sun PD; Wellems TE
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6285-6290. PubMed ID: 29844160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
    Birth D; Kao WC; Hunte C
    Nat Commun; 2014 Jun; 5():4029. PubMed ID: 24893593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.
    Song Z; Clain J; Iorga BI; Yi Z; Fisher N; Meunier B
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4053-8. PubMed ID: 25918152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.